美 ‘여성용 비아그라’ 제조사, ‘1조 2천 억원’에 팔려 Valeant snaps up 'Female Viagra' maker Sprout for $1 billion(VIDEO)

미 제약회사 스프라우트(SPROUT)

VIDEO

http://for.tn/1J7j3wc

edited by kcontents 

케이콘텐츠 편집

캐나다의 제약 대기업인 밸리언트는 20일, ‘여성용 비아그라’로 불리는 여성의 성적 욕구 저하 장애 치료약을 만든 미국의 제약회사를 인수하기로 합의했다고 발표했다. 인수금액은 약 10억 달러(1조 2천 억원)로, 향후 판매 실적에 대응해 금액을 높여간다. 미 제약회사는 스프라우트. 이 회사의 치료약인 ‘애디’는 미 식품의약국(FDA)으로부터 처방약으로 18일 인가를 받았다. 올해 10월 중순부터 미국에서 판매가 가능해질 전망이다. 밸리언트는 많은 주목을 받고 있는 애디의 전 세계 판매를 목표로 자금을 투입해 향후 판매 증가를 노린다는 전략이다. 올해 7~9월기에 인수 절차완료를 전망하고 있으며 스프라우트는 밸리언트의 사업부문이 된다.【뉴욕 교도】 Valeant snaps up 'Female Viagra' maker Sprout for $1 billion by  Geoffrey Smith  @Geoffreytsmit A trademark piece of fast dealing from the acquisition-driven Canadian company. The ink is hardly dry on the approval letter from the Food and Drug Administration, but the makers of Addyi, the “Female Viagra,” have decided it’s time to cash out. Canadian-based Valeant Pharmaceuticals  VRX -6.47%  said Thursday it’s agreed to buy Sprout Pharmaceuticals Inc. for an initial $1 billion in cash, generating an immediate and hefty pay-day for the pint-sized Raleigh, NC-based firm. The bill may rise as Addyi passes certain (unspecified) milestones in sales and profits It’s only two days since the FDA gave Addyi its blessing, making it the first officially sanctioned treatment for boosting female sexual desire in the U.S.. Valeant is betting that the drug will be the same kind of runaway success as Viagra, Pfizer Inc’s  PFE -1.59% pioneering treatment for male erectile dysfunction, 15 years ago. Valeant is due to pay $500 million upon closing the transaction (expected by the end of September) and another $500 million in the first quarter of 2016. It expects Addyi to go on sale in the U.S. in the fourth quarter, and to add moderately to Valeant’s earnings in 2016, according to the company’s statement. Sprout will remain headquartered in Raleigh as a division of Valeant, a group that habitually prefers to buy drugs developed by others rather than develop them itself. A person familiar with the situation told Fortune that “Valeant and Sprout had been in talks for about three to four weeks and had structured the deal so that the terms could be finalized quickly after Addyi’s approval.” “Delivering a first-ever treatment for a commonly reported form of female sexual dysfunction gives us the perfect opportunity to establish a new portfolio of important medications that uniquely impact women,” Valeant chairman and CEO Michael Pearson said in the statement. Sprout CEO Cindy Whitehead commented that Valeant’s international reach “offers us a global footprint that could eventually bring Addyi to women across the globe.” http://fortune.com/2015/08/20/valeant-snaps-up-female-viagra-maker-sprout-for-1-billion/ 케이콘텐츠  kcontents

"from past to future"

데일리건설뉴스 construction news

콘페이퍼 conpaper

.